You Never Forget Your First

BY Kevin McCormack
Jake Javier
Jake Javier: Photo by Michael Clemens
Now that we have 64 clinical trials that we have funded (plus a few dozen more where we supported the early stage research) it’s sometimes hard to remember the details of each trial. But there is one you never forget. The very first clinical trial you funded. And we just got some encouraging news about it.

Way back in 2011 CIRM funded a clinical trial with a company called Geron, targeting spinal cord injuries. It was not only the first clinical trial we funded, it was also the first clinical trial involving the use of embryonic stem cells that was approved by the US Food and Drug Administration (FDA).

But in November of that year Geron decided to change its business plan and canceled the trial. We got all our money back – plus interest – but it was still terribly disappointing to us and to everyone who had hopes the research would help people with severe spinal cord injuries.

Fast forward three years and a company called Asterias picked up where Geron left off, getting permission from the FDA to run a clinical trial using the same approach for spinal cord injuries. Once again CIRM funded the project.

The results from this Phase 1 trial were, to say the least, encouraging.

We profiled two of the patients treated in this group who seemed to benefit a lot from the therapy; Jake Javier and Kris Boesen.

Kris Boesen
Kris Boesen: Photo courtesy USC
But after the initial trial it felt like someone hit the pause button. Asterias was bought up by BioTime which changed its name to Lineage Cell Therapeutics and moved much of the OPC1 spinal cord injury program to Israel. Then last week Lineage announced it was unpausing the program.

In a news release they announced that by moving the program to their cGMP manufacturing plant in Israel they were able to make “process improvements” in the program and, more importantly; “ Lineage intends to meet with the U.S. Food and Drug Administration (FDA) to discuss further development of the OPC1 program by the end of 2020.”

Brian M. Culley, Lineage’s CEO said: “We have worked diligently over the past year to transition all manufacturing activities for the OPC1 program to our in-house cGMP facility, where our experienced cell therapy production team could develop and deploy much-needed improvements and modernization to the production and analytical processes. This work has achieved significantly better efficiency and improved quality control, which we expect will enable a consistent supply of material to support a late-stage clinical trial of OPC1. With these necessary steps now completed, our focus turns to developing a “thaw-and-inject” formulation and superior delivery tools, to enable an easier surgical procedure and facilitate faster enrollment in the next clinical trial. We also are evaluating ways to return OPC1 to the clinic sooner than originally planned, reflecting our view of compelling clinical data which continues to read out from the 25-patient phase 1/2a SCiStar study.”

So, almost a decade after we first became involved with this project, we’re happy to say it’s alive and seemingly well and getting ready to take the next step in helping people with spinal cord injuries. We’ll let you know how it goes.

One last thing. One of the reasons we are such fans of the approach is Jake Javier. We have come to know and admire him and watch him fight back from his injury. He is a remarkable young man in many ways. He is now a student at Cal Poly where they made this video about him.

Originally published on The Official Blog of CIRM, California's Stem Cell Agency

Update on Clinical Trials

FROM The Director
Update on clinical trials
Since our last newsletter, two peer reviewed papers have been published reporting results of clinical trials for spinal cord injury and there have been significant updates on the results of a third ongoing trial.

The SCiStar study: The company Asterias has completed enrollment and dosing in all 5 of its planned SCiStar study Cohorts. This is a Phase 1/2a clinical trial to evaluate safety and potential efficacy for severe cervical spinal cord injury. Readers of Spinal Connections know that the foundation for the Asterias trial was the paper in 2005 by Hans Keirstead at the RIRC (Keirstead, H.S., Bernal, G., Nistor, G., Totoiu, M., Cloutier, F., Sharp, K., and Steward O. Human stem cell derivatives remyelinate and restore locomotion after spinal injury. J. Neurosci., 25, 4694-4705). The clinical trial for oligodendrocyte precursor cells (OPCs) was initially launched by the company Geron and was the first ever trial for human stem cells for spinal cord injury. This trial was terminated for economic reasons and the company Geron folded but the company Asterias re-booted the trial with their product called “AST-OPC1”.

On July 31, 2018 Asterias reported 12 month data for Cohort 3 and 4 updating previous reports on the data from earlier time points. Those of you who have been following this know that there are 5 Cohorts in the trial. Cohort 3 involves 6 subjects with cervical level injuries who are motor complete (AIS-A) who received 20 million cells. Cohort 4 involves 6 subjects with cervical level injuries who are AIS-B who received 20 million cells.

Overall, there continues to be a positive safety profile with no serious adverse effects related to the transplanted cells. Magnetic resonance imaging (MRI) studies at 12 months are consistent with the formation of a tissue matrix at the injury site in 92% (11/12) subjects, suggesting reduction in cavity formation. At 12 months 100% (6/6) subjects in Cohort 3 have recovered at least one motor level on at least one side and one subject recovered two motor levels on one side. For the combined data for Cohorts 2-4, 94% (17/18) subjects recovered at least one motor level on at least one side. Asterias expects to publish 12 month data for the entire study in the first quarter of 2019.

On October 31, 2018, Asterias announced that an independent Data Review Panel recommended moving forward with the clinical development of OPC1. The next step is a meeting with the Food and Drug Administration (FDA) to discuss the path to development and trial design for a controlled Phase 2 clinical trial that could begin in 2020.

Data from the Phase 1/2a clinical trial continues to be promising, but there is a looming hurdle for Asterias in terms of funding to go forward. The larger Phase 2 controlled efficacy trial will cost tens of millions of dollars.

Update on Stem Cell Trials for Spinal Cord Injury

BY Oswald Steward
Update on stem cell trials for spinal cord injury
There is continuing positive news for the clinical trial being conducted by the company “Asterias” involving transplants of oligodendrocyte precursor cells (OPCs) derived from human embryonic stem cells. In this “Director’s Column”, I try to present things in a conservative and cautious way, but the latest news is really exciting and points back to fundamental discoveries here at the RIRC.

Readers of “Spinal Connections” know that the foundation for the Asterias trial was the paper in 2005 by Hans Keirstead at the RIRC (Keirstead, H.S., Bernal, G., Nistor, G., Totoiu, M., Cloutier, F., Sharp, K., and Steward O. Human stem cell derivatives remyelinate and restore locomotion after spinal injury. J. Neurosci., 25, 4694-4705).

After a lot of preclinical work, the clinical trial for oligodendrocyte precursor cells (OPCs) was launched by the company “Geron” and was the first ever trial for human stem cells for spinal cord injury. This trial was terminated for economic reasons and the company Geron folded but the company “Asterias” was founded and re-booted the trial with their product called “AST-OPC1”.

Cohort 2 (AIS-A 10 million cells) motor level recovery vs. comparators
Since our last newsletter, the company has continued to provide interim reports on the results of the trial involving 6 subjects with cervical level injuries that had received 10 million OPCs (called “cohort 2”). These subjects had shown improvement in arm, hand and finger function at 3-months and 6-months following treatment, and the 9 month data showed more improvement. Then, just as we were finalizing this article in early October, Asterias released 12 month data on the 6 subjects in cohort 2. There was additional motor improvement so that 4 of the 6 subjects (67%) now exhibited at least two motor levels of improvement over baseline on at least one side and one achieved 3 motor levels of improvement on one side. This extent of recovery is higher than what would be expected based on independent data for historical controls. It’s important to emphasize that regaining two motor levels can improve ability to perform daily activities like feeding, dressing and bathing and reduce the overall level of assistance the person requires.

An article in the San Francisco Chronicle by Erin Allday quotes lead investigator, Dr. Richard Fessler, Professor of Neurosurgery at Rush University Medical Center: “Scientifically, I have to say we don’t know for sure if it’s the stem cells. But I’ve been treating these kinds of patients for 30 years, and I’ve never seen anything like this before.”

Although the current reports are very exciting, it’s important to keep in mind that the treatment being tested is only a start. If this was a computer application, you could think of this as version 1.0. The original science documented a measurable but modest improvement in motor function in rats, but with this as a start, we can move on to find better and more effective therapies (version 1.1, 1.2, etc.).

With an eye toward the need to develop more effective treatments in the future, it’s useful to look back at the roots of this story because it highlights the huge impact of private donations. The initial research by Dr. Kierstead’s group at RIRC was supported in part by private donations to our Center. One major finding in the original paper was that OPC transplants during the “acute” post-injury period improved function whereas transplants into rats with chronic injuries didn’t. We were able to do the study of chronically-injured rats because the animals had been generated for our summer boot camp “Techniques in Spinal Cord Injury Research”. We were able to maintain the rats into the chronic period because of private donations.

Private donations were critical for the initial pilot experiments that provided critical preliminary data for grant proposals. The first actual grant to support the work came from the “Roman Reed Spinal Cord Injury Research Act” and then Dr. Keirstead received a research grant in the initial round of funding by CIRM to support his stem cell research at RIRC. And of course, CIRM funding has been critical for the clinical trial by Geron and then Asterias.

To put all this in perspective, it’s worth remembering that when the RIRC was launched in 1999, there were no ongoing trials for people with SCI. We’ve come a long way and there is great optimism that we are on track for even greater advances. However, private donations are still the most important driving force for the first stage of innovation.

The RIRC Welcomes New Faculty Member - Dr. Harriet Chang

Harriet Chang joins Reeve-Irvine Research Center as faculty member
Dr. Chang has been working in the urological fields for over 10 years. Her predoctoral training was with Dr. William C. de Groat, who is recognized as one of the world leaders in research on neural control of bladder function. Dr. de Groat received the Reeve-Irvine Research medal in 2009 for his fundamental studies in this area. Dr. Chang’s expertise is in pharmacological modulation of bladder function following spinal cord injury (SCI). Her studies focus on rodent models, and the control of a muscle called the external urethral sphincter. To void the bladder in a normal way requires that two physiological actions occur simultaneously. The bladder (which is actually a muscle) has to contract and at the same time, the external urethral sphincter, which is basically a biological valve, has to open. These two actions have to occur in “synergy” (which means together). People who have suffered a spinal cord injury often suffer from a condition called “dys-synergia”, in which there is bladder contraction triggered by a full bladder at the same time that the sphincter (the valve) doesn’t open. This causes a pathological increase in pressure within the bladder, which pushes urine back up into the kidneys. All of this greatly increases the chances for kidney damage and urinary tract infections. Thus, figuring out how to control the external urethral sphincter is of great importance.

examples of urethral activation
Dr. Chang is currently funded by NIH/NIDDK to investigate the urethral function by using spinal cord epidural stimulation (SCS) in the rodent model of SCI. SCS is a well-developed and widely used technique on neuromodulation, especially for neuropathic pain and the recent studies of locomotion. Dr. Chang first used this technique on modulation of urethral sphincter focusing on the improvements of voiding function in rodents with SCI.

The use of SCS over the upper lumbar cord (L3) evokes the urethral relaxation (Figure 1). This technique improves the voiding efficiency and promotes urine expulsion in the rodents with dys-synergia after SCI.

Dr. Chang’s team also applies L3/SCS to investigate the effect on bladder overactivity in rodents. Overactive bladders (OAB) has the symptoms including frequent bladder contractions, urgency and urine leakage, commonly seen in people over 40 years old and men with prostate enlargement. L3/SCS increases the bladder capacity and decrease the bladder contractions (Figure 2).

Dr. Chang wishes to establish the foundation for studies of mechanisms associated with bladder dysfunction and contributes to improve voiding efficiency. Dr. Chang will explore new therapeutic approaches to these problems using pharmacological modulation and artificial electrical stimulation.

UCI Heads $8 Million NSF-Funded Project to Develop Brain-Computer Interface

Implantable technology to restore sensation and walking in spinal cord injury patients

Implantable technology to restore sensation and walking in spinal cord injury patients
The National Science Foundation has awarded $8 million to a consortium led by the University of California, Irvine to develop a brain-computer interface that can restore walking ability and sensation in individuals with spinal cord injury. This initiative represents the largest NSF award received by faculty researchers in the UCI engineering and medicine schools.“The goal of this multidisciplinary project is to create an implantable system that by circumventing the damaged portion of the spinal cord can enable patients with these injuries to regain feeling in their legs and walk again,” said principal investigator Payam Heydari, UCI professor of electrical engineering & computer science.

“Spinal cord injuries are devastating and have a profoundly negative impact on independence and quality of life of those affected,” he added. “These resulting disabilities cost the U.S. roughly $50 billion per year in primary and secondary healthcare expenditures, so we hope that our work can solve a major national public health problem,"

The five-year grant, sponsored by the NSF’s Cyber-Physical Systems Frontier program, will be divided among UCI, California Institute of Technology and the University of Southern California. Heydari’s co-principal investigators on the project are Zoran Nenadic, UCI professor of biomedical engineering; An Do, UCI assistant clinical professor of neurology; Richard Andersen, the James G. Boswell Professor of neuroscience at Caltech; and Charles Liu, professor of neurological surgery at Keck School of Medicine of USC.

Nenadic said that the UCI research team has been working in recent years to miniaturize brain-computer-interface systems, shrinking them from the size of a desktop computer to pacemaker scale. Nenadic and Do collaborated previously on a proof-of-concept study to implement a brain-computer interface which enabled a paraplegic man to walk a short distance. The goal of this new NSF-funded project is to perfect the technology and decrease its size.

“Professor Heydari’s lab, which specializes in low-power, nano-scale electronics, designed and implemented several critical integrated circuits that makes scaling to this small size possible,” he added.

This new initiative will focus on converting existing technology into a fully implantable version which will implemented in a manner similar to deep brain stimulators. To test the technology, the UCI team will collaborate with Caltech and USC on clinical studies in volunteers with spinal cord injury.“Since these systems are fully implantable, they will be inconspicuous, work around the clock and access much stronger brain signals, facilitating highly accurate control of movement,” said Nenadic.

Do, an expert in neurorehabilitation, sees potential beyond helping individuals with spinal cord injury. “Once these systems are FDA-approved, their application can be expanded to people affected by disability due to stroke or traumatic brain injury,” he said. “The study also will greatly expand our knowledge of how the human brain controls walking and processes sensation – knowledge that can help researchers better understand disease processes that affect these functions.”

The Cyber-Physical Systems Frontier program is one of the largest within the NSF, providing funding for major efforts that identify and address critical problems which have the potential to be solved through the use of electronic, computing and information technologies.

Leaving a Legacy of Hope

“From a tiny acorn grows the mighty oak." Like the acorn in this old maxim, regardless of the size of a bequest, it can grow into a lasting legacy.

In August of this year, the Reeve-Irvine Research Center was the beneficiary of a generous planned gift from Albert N. Goldfeder. This gift established an endowment in Mr. Goldfeder’s name that will exist in perpetuity at the RIRC along with $40,000 for current use for public educational programs and scientific symposia and to support pilot research studies on innovative approaches to improve function after spinal cord injury. Mr. Goldfeder will be publically acknowledged for his generosity at the 2018 Reeve-Irvine Research Medal Symposium (see cover article), which will be open to the public. His generosity has opened the door to so many opportunities for our Center, providing funding to accelerate discovery, but also allow for flexibility to rapidly address new opportunities.

A bequest is one of the easiest forms of gifts that you can make to support the Reeve-Irvine Research Center. Through your bequest, you have the opportunity to establish a lasting legacy that offers hope to thousands, and to shape the lives of future generations. Planned giving is a way to remember a friend or relative, fulfill a desire to help others less fortunate or give back to the community, or make an investment that will grow knowledge and advance science. Your donation could lead to a key discovery that will be linked to your contribution forever! And of course, planned giving can bring important tax benefits.
Every dollar makes the research go further, faster.

Below are some examples of ways planned gifts make a difference.
● Seed Money for new ‘out of the box’ research ideas, support for new projects that are spinoffs of existing projects to improve the quality of the potential treatment, as well as advancing projects that are underfunded. These pilot studies will provide critical preliminary data for future grant proposals.
● Accelerating progress - exciting new studies may have funding that is distributed over years but the studies could be done more quickly. You who are living with SCI want rapid progress and our researchers are ready and able to move research forward without delay to test potential therapies. Any research project requires technical support; lab items must be ordered, finances must be tracked, animal research protocols must be prepared, and progress reports are required. Funds that are restricted to research cannot be used for these critical support services. Some equipment may be too costly for standard grant applications and/or may be restricted to one specific project. Bequeathed gifts allows for cross use of equipment maximizing impact not only in the immediate future but in perpetuity.
● Public Events- give an opportunity for those who suffer with an SCI injury to speak directly to our scientists to ask questions about their injury and to see first-hand the latest research that is being conducted through on-site tours.
● Scientific Symposia- Scientific meetings are one of the primary venues for scientists to share their findings before publication and establish new collaborations. This is a key to the process of science that leads to innovations that come from thinking as a team.

All of us at the Reeve-Irvine Research Center would like to send our heartfelt thanks to the Goldfeder family. It is private gifts like his that play a critical role in propelling spinal cord injury research programs and explore creative opportunities that cannot be explored through traditional funding sources. We are grateful to Mr. Goldfeder for his interest and support of the RIRC.

Update on Neuronal Vitality with PTEN Deletion

BY Oswald Steward
Neuronal vitality with PTEN deletion
A high magnification view of a PTEN immunostained section using phase-contrast microscopy from the brain of a mouse one year following neonatal conditional PTEN deletion in the motor cortex. Phase imaging was used to verify the presence of large layer V PTEN negative "ghost cells", which appear blue in this image. Neighboring PTEN positive neurons are stained brown and are visibly smaller than the ghost cells.
We reported in the last issue on Erin Gutilla's paper on long-term consequences of PTEN deletion (Gutilla et al., 2016). The paper had just been released electronically, but at that time, we didn't know that it had been selected as the cover image for the Journal. This is a nice highlight of our research!

Erin, who is an MD/PhD student, is completing her dissertation research in the spring. In addition to the paper above, she was invited to submit a review for the journal “Neural Regeneration Research”. This is another nice recognition of the impact and importance of her discoveries.

The review summarized our findings that deleting PTEN in young (or developing) neurons in the way that enabled axon regeneration didn't seem to be harmful. Even more important, neurons lacking PTEN appeared more robust and healthy than other neurons more than 1 year after the intervention. Erin's dissertation research is following up on this very interesting finding. She'll complete her PhD research in the spring and then back to medical school. Look forward to further updates in our next newsletter!

If you would like to review the scientific article
click this link.

Gutilla, E.A., Buyukozturk, M.M., Steward, 0. (2016) Long-term consequences of conditional genetic deletion of PTEN in the sensorimotorcortex of neonatal mice. Exp. Neurol. 279, 27-39
Gutilla, E. A., and Steward, 0 . (2016) Selective neuronal PTEN deletion: Can we take the brakes off of growth without losing control? Neural Regeneration Research. 11(8): 1201-1203. (

Update on Stem Cell Trials for Spinal Cord Injury

BY Oswald Steward
Update on stem cell trials for spinal cord injury
In our spring newsletter, we reported on the results of the trial being carried out by the company “Asterias”, in which people who have suffered spinal cord injuries are receiving surgical injections of oligodendrocyteprecursor cells (OPCs) derived from human embryonic stem cells (hECSs) into their spinal cords. The OPC trial was based on research carried out by Hans Keirstead at the RIRC, and the current trial is called the “ST-OPCI SCiStar study”. On November 14, Asterias announced that enrollment in the trial had been accelerated with three patients having received cell injections in early November. In addition to the patient cohorts that previously received doses of 2 million and 10 million cells, two patients have now received the maximum dose of 20 million cells, which is thought to be roughly comparable to what the rats received in the initial study.

The two patients who received the 20 million cell dose are cervical AIS-A, meaning complete loss of motor and sensory function below the cervical injury site. AIS-8 patients have similar cervical injuries and complete motor loss but retain some sensory function, and Asterias believes AIS-8 patients may be particularly responsive to AST-OPCI due to the larger amount of intact spinal tissue remaining at the injury site. The company plans to report 6 month efficacy and safety data in January 2017. The “ST-OPCI SCiStar study” is an FDA approved trial that has been extensively reviewed by scientific and medical experts. The data from the trial will be fully analyzed and reported. The carefully controlled and FDA approved clinical trial that Asterias is running is in stark contrast to literally hundreds of “Stem Cell Clinics” that are popping up all over the United States that deliver untested “stem cell” products to those who are able to pay. In September, the FDA held a 2-day public meeting on possible changes in rules for stem cell clinics in the United States. Surprisingly, there are few rules and little oversight of such clinics, raising concerns that clients may be getting noncompliant cell-based interventions.

Tighter regulations may not sound like a good thing, and some people came to the meeting to testify that they had benefitted from treatments they had received from stem cell clinics. On the other hand, FDA regulations are an important reason why we can trust that the medications and treatments that we receive (and pay for) have been tested for safety and effectiveness. Patient safety IS at stake, and very few of us can afford to pay tens of thousands of dollars for something that doesn't work. The problem is that in an un-regulated market, it's not possible for most consumers to distinguish between treatments that have been tested and shown to be safe and effective vs. treatments that have never actually been tested at all. As Dr. Larry Goldstein wrote in an e-mail: “Thoughtful FDA regulation of the growing stem cell industry is essential to help consumers distinguish fraudulent claims from legitimate clinical trials, research and therapy development”.

The other huge problem is that the term “stem cell” is now being used for a number of different cell types and treatments. Clinic websites advertise different products, but there's no oversight or independent validation of claims that a particular product is actually what the clinic says it is. There's no playbook that consumers can use to figure it all out.

And there are more examples of some really ugly consequences. In July, the highly respected New England Journal of Medicine published a scientific report on a man who developed a tumor in his spinal cord after receiving infusions of different types of stem cells and a transplant of “fetal neural stem cells” into his spinal cord. Berkowitz et al., 2016, Glioproliferative lesion of the spinal cord as a complication of “Stem-Cell Tourism” (http://www.nejm.or g/doi/fu ll/ I 0.1056/NE!Mc 1600188). The patient developed pain that got worse over time and increasing paraplegia. A biopsy of the tumor revealed a mass comprised of cells from another human being that were proliferative (meaning that the tumor was growing). This article concludes: “The unregulated commercial stem-cell industry is not only potentially harmful to individual patients but also undermines attempts to study stem-cell therapies in clinical trials. This case provides further support for the conclusions of an article advocating increased investigation of commercial stem-cell clinics and increased patient education regarding the risks of stem-cell tourism. Such experimental treatments must be studied in a safe, regulated environment.” So, as we've cautioned before, y'all be careful out there!

Trainees Taking Next Steps

BY Steward Lab
One of the important functions of the RIRC is training young scientists for research on spinal cord injury, nerve regeneration and stem cell applications. Our trainees then go on to positions at other universities or private companies, thereby expanding the spinal cord injury workforce. The most important metric is the success our training fellows have in taking their career in the direction they desire.

Dr. Zack Gallaher
Dr. Zack Gallaher
Accordingly, we are pleased to announce that two RIRC postdoctoral fellows have completed their training and been offered positions at other universities. Dr. Zack Gallaher has just been recruited to a faculty position at the University of Western Washington. Zack and his family come from Washington state and are thrilled to be returning to the area and their families there. In his time at RIRC, Dr. Gallaher carried out a comprehensive experiment to test whether manipulations of the PTEN gene would enhance regeneration of peripheral nerves in the same way that occurs with nerve connections (axons) in the central nervous system (CNS). Dr. Gallaher discovered that manipulations of PTEN did enhance regeneration of peripheral nerve, but not as extensively as in the central nervous system. A major research paper describing these studies is under review for publication.

Dr. Aminata Coulibaly
Dr. Aminata Coulibaly
Dr. Aminata Coulibaly will be completing her postdoctoral fellowship with Os Steward in January, and was offered a position as Research Associate at the University of Virginia. She will be moving to UVA in January to undertake studies on the specialized immune system that serves the brain. This is a new and exciting area of research launched in 2015 by the discovery of a brain lymphatic system. This discovery was a candidate for one of the top 10 discoveries of the year in 2015. Dr. Coulibaly's research at RIRC focused on how nerve cells and glial cells responded to deletion of the gene PTEN in the cortex in the way that we have shown to enhance regeneration after spinal cord injury. She'll complete her studies in January, but it is already clear that there are some very exciting discoveries that we will describe in detail in future Spinal Connections.

Dr. Patricia Salgado
Drs. Patricia Salgado & Os Steward
The Reeve-Irvine Research Center would also like to congratulate Dr. Patricia Salgado who completed her final requirements for her Ph.D. in August! Dr. Salgado's Dissertation, entitled "Phosphorylation of ribosomal protein S6 as a mechanism to regulate translation at activated synapses" described novel molecular mechanisms of synaptic changes due to experience. A central theory of modem neuroscience is that changes in synapses due to activity are the way the brain stores memories. For example, brief patterns of activity actually change the structure of synapses, increasing their strength. Repeated activity patterns then reinforce the structural changes, and this underlies long-term memory. Patty discovered a fundamental mechanism underlying this process through which signals from synapses trigger molecular changes in the machinery that synthesizes proteins, specifically, small structures in the cell called "ribosomes". These changes in ribosomes then change the types of proteins that are being produced at synapses. Our graduate researchers are an important part of our RIRC team please join us in congratulating Dr. Salgado and help us to recognize her for her research accomplishments.

The Move To Move Continues

BY Steward Lab
In the winter of 2010 the RIRC announced the launching of the Corticospinal Tract PTEN Regeneration Project by Dr. Zhigang He from the Children's Hospital, Harvard and Dr. Oswald Steward at the Reeve-Irvine Research Center, UCI. In this study, Drs. He and Steward devised a way to induce regeneration of a pathway that controls voluntary motor function after spinal cord injury. This is accomplished by blocking a naturally occurring human enzyme known at PTEN which enables unprecedented nerve regeneration. This study showed clearly that shutting off PTEN allows robust regeneration of the corticospinal tract, previously considered the most difficuIt tract to regenerate.

After learning of these advances the Wentz family decided to establish the “Z Fund” named after Zack Wentz who suffered a spinal cord injury at the age of 15 at a ski resort when the family was on vacation. The Wentz family described the following years as an emotional roller coaster and Zack was faced with learning to readjust his life from being a very active teenager to one who faced the challenges of living with paralysis from the chest down. The purpose of the Z Fund was to raise money for SCI research and the CST PTEN Regneration project and raised close to $120,000 at Stanford University in 2010. In 2011 the Wentz family pulled together another event they called the “Move to Move” that raised over $100,000. These events were key in providing the funding to carry out critical studies that generated preliminary data for two NIH grants to Drs. He and Steward which allowed for an additional 5 years of research and yielded well over 1.5 million in research funding that otherwise would not have been possible.

Zack Wentz and family
Zack Wentz & family are recognized for their contributions
Since the Z Fund was established in 2010, Zack worked at the Riekes Center for Human Enhancement as a piano teacher, teaching a wide variety of students how to play the piano by ear, just as he taught himself how to play the piano! Simultaneously he worked at a Mexican restaurant, as well as at a summer camp three consecutive summers.

He received word that he was accepted to the University of Southern California (USC), and was fortunate enough to receive a “Swim With Mike Scholarship”, a scholarship dedicated to providing financial resources for physically challenged athletes.

In 2014, Zack pledged and ultimately became an active member of Delta Omicron Zeta, USC's leadership fraternity. He worked in the USC Athletic Department as an intern assisting in the development of the Heritage Association, an organization whose goal is to create a unified community among USC student-athletes and student-athlete alumni through philanthropy.

In 2015, Zack applied for the Lime Connect Fellowship program, to which he was ultimately selected as one of twenty fellows to participate in a highly competitive leadership and development program in New York City for students with disabilities. Additionally, Zack founded USC's 1st Annual Wheelchair Basketball Tournament, an idea that he developed and included in his application to USC. The tournament has been a wild success each of its first two years, including participation from over 100 USC students, as well as participation from USC's Men's and Women's Basketball Teams. Zack has already started preparing for the 3rd annual WBT this upcoming spring!

In the spring of 2016, Zack went through a grueling pledge process that culminated with his becoming a Trojan Knight, USC's guardians of tradition. “The Three Pillars of our Trojan Knights organization are Brotherhood, Philanthropy, and Spirit. We are the guys who are front row at every football and basketball game with our chests painted. And we are the guys who put on numerous philanthropy events around the community, including USC's biggest philanthropy: the big “Swim with Mike” event in April”.

In the summer of 2016, Zach got a job as a social media and campus ambassador for a sports news company called The Lead Sports. He also started volunteering with Dharma Rescue, a volunteer organization dedicated to rescuing disabled dogs and training them to become therapy dogs. Finally, this past fall semester, Zack inspired a position within USC's Undergraduate Student Government and has held that position since. He serves as the Disability/Accessibility Issues Advisor on USG's Board of Advisors. This position has had countless initiatives regarding how to make USC a more accessible place, and holding this position within USC's Undergraduate Student Government has expanded Zack's resources immensely, which has been conducive to more productivity with his initiatives. These initiatives range from improving accessibility (which covers all sorts of disabilities) in dining halls, dorms, and classrooms, to being a liaison and meeting with architects working on renovations for various USC sporting venues.

Zack did not let his challenges slow him down and neither have the research teams working on the CST PTEN Regeneration project. Since the initial launch of this project, the Steward Lab published papers in 2014 and 2015 showing that CST regeneration was accompanied by recovery of motor function. And the latest new breakthrough discussed in a recent issue of our Spinal Connections that discusses collaborator Dr. Kai Liu's first author article in Nature Neuroscience showing that it is possible to induce CST regeneration in a chronic setting! (see cover story of Summer 2015). This is the most promising finding in chronic regeneration that we have seen to date and we are all very excited about the future of this project.

We would like to congratulate Zack Wentz on his amazing accomplishments despite challenges that faced him, and thank the Wentz Family for showing that perseverance pays off! There is so much promise in the future of research that could help Zack and many others who could benefit from potential therapies stemming from research conducted at the RIRC. All of us are grateful to the many private gifts we receive that help propel these important projects forward.

If you are interested in supporting this project or the RIRC please consider giving online by or contact Tania Jope by phone: (949) 824-5925 or email:

Trotting off the Turkey Tummy

Plymouth Rock n' Run
In its 9th year of fundraising for the Reeve-Irvine Research Center, Research for Cure’s Plymouth Rock 'n' Run team put on another successful 5k/10k Thanksgiving Day "Turkey Trot", playing host to 2500 participants, exhibitors, and spectators. The event, held annually at Yorba Regional Park in Anaheim Hills CA, was established in 2006 by the Johnson family of Yorba Linda, who helped again this year securing sponsorships and prizes. Tim Johnson, co-founder of PRNR, was the start-line announcer for the 5k and 1Ok races and kicked off both with an inspiring speech before the starting horn was sounded.

This year’s finish line festival featured a silent auction, prize wheel for the kids, vendors selling gifts for the holidays and even a mobile tropical cage with numerous trained parrots! Family Tree Produce provided complimentary food at the finish line for the participants, and a special coffee booth open to all attendees was provided by Influence Church. Cure Medical helped to sponsor some of the cost for the event T-shirts for everyone who participated. Task Force Heroes again donated participant goodie bags and staffed gear check at the event.

Plymouth Rock n' Run finish line
We are so grateful to all those who donate their time and talent to make this event a huge success! Event managers James and Deborah Scott worked tirelessly as they have in years past to produce a well-organized race, with assistance from Michelle Laizure, as well as Travis Torres and his team from Bear Pit Gym & Fitness Center. Many other volunteers from local school organizations, churches, businesses, and other groups in the community also pitched in to assist with registration, event and course setup/teardown and handling of numerous other race details before and during the event. For the fourth consecutive year, Allan Cason from APC Entertainment served as DJ and master of ceremonies. He sang incredible renditions of "The Star-Spangled Banner" and "God Bless the USA (aka "Proud to be an American") to start off the 1Ok an 5k races, respectively, which got our racers in the spirit oft e occasion and ready to run!

Plymouth Rock n' Run volunteers
The Research for Cure 501(c )(3) charity was created by Fran Lopes in 2002, and to date has raised over $900,000 from Plymouth Rock 'n' Run, golf tournaments and other fundraising events to benefit RIRC. The PRNR team has already starting planning its 2017 Thanksgiving Day Turkey Trot, marking its 10-year anniversary. Come join us for a morning filled with fun and healthy activity in support of the Reeve-Irvine Research Center! You can organize your own fundraising team with your family and friends and help to make the race proceeds even more successful. Or just show up in costume and be in the pool of folks who may win a prize for best costume! If you cannot make it to the race please consider taking part in the virtual run, join a team on line or help with sponsorship. There are so many ways to support this amazing group in their efforts to make a difference in the lives of those who need to believe in a better tomorrow.For more information about the race and sponsorship opportunities, please visit the Plymouth Rock 'n' Run website at or contact Tania Jope at (949) 824-5925 .

PTEN deletion makes healthy, happy neurons. One more step along the path.

BY Steward Lab
Healthy happy neurons with PTEN deletion
Healthy, happy neurons with PTEN deletion. The image shows neurons that give rise to the corticospinal tract (CST) immunostained for a molecule that reflects activation of a growth-promoting pathway (the phosphorylated form of ribosomal protein S6).
We’ve been reporting regularly on our progress in the CST/PTEN project to develop interventions to regenerate nerve connections (axons) after spinal cord injury (SCI). The latest advance is described in a paper by Erin Gutilla, an M.D./Ph.D. student in Os Steward’s lab, reporting that long-term deletion of PTEN in neurons not only isn’t harmful; it causes neurons to grow and...well, look young again.

PTEN negatively regulates an intracellular signaling pathway called AKT/mTOR. In early development, the pathway is turned on by growth factors acting through receptors, which stimulates cell division and cell growth. As organisms mature to adulthood, PTEN turns on and shuts down AKT/mTOR. So, deleting PTEN takes the brakes off of the growth-promoting AKT/mTOR pathway, which enables nerve cells to regenerate their axons after spinal cord injury. In essence, what PTEN deletion seems to do is turn back the developmental clock to make neurons into early teenagers in a growth spurt.

Like almost every powerful therapy, however, there are potential concerns. Turning nerve cells into early teenagers primes them for a growth spurt, but as we all know, teenagers can be difficult. Parents sometimes may wonder whether an alien has taken over a teenager’s body. I could go on, but enough on that…

One concern was that deleting PTEN might increase the risk of tumors. PTEN is a tumor suppressor gene. Mutations in PTEN have been identified in many cancers, and mutating PTEN in early development can cause overgrowth of the brain, called macrocephaly. For these reasons, it was important to determine whether there were negative consequences of deleting PTEN in nerve cells in the way that was needed to induce regeneration.

In the study that just came out (Gutilla et al., 2016) we deleted PTEN in 1 day old mice and then examined their brains when they were up to 1.5 years old. The lifespan of mice is a bit over 2 years, so 1.5 years is the equivalent of retirement age. Importantly, there was no evidence of any neuropathology or tumors. Instead, the neurons lacking PTEN actually were larger and more healthy-looking than neurons in other parts of the brain (Figure), and looked like neurons in young adult mice. It was as if the aging clock had been turned back.

The lack of any detectable neuropathology due to PTEN deletion is very good news, suggesting that long-term deletion of PTEN selectively in neurons may have relatively low risk. Of course, there will need to be more safety testing but this is an encouraging assessment.

The broader implication of these findings is that targeting PTEN may be a way to reduce neuronal atrophy and death in neurodegenerative diseases like Parkinson’s disease, Alzheimer’s Disease, and ALS and even reverse “normal” age related deterioration of neurons. Erin Gutilla will be completing her dissertation research in the next year by exploring these questions.

Mark Tuszynski Awarded the Reeve-Irvine Research Medal

BY Oswald Steward
Mark Tuszynski awarded the Reeve-Irvine Research Medal
Dr. Oswald Steward (left) RIRC Director and James Swinden (right) of the Joan Irvine Smith & Athalie R. Clarke Foundation award Mark Tuszynski the Reeve-Irvine Research Medal.
The Reeve-Irvine Medal Symposium celebrated Mark Tuszynski as the recipient of the Reeve-Irvine Research Medal. In 1996 well known philanthropist Joan Irvine Smith established an annual award originally named the “Christopher Reeve Research Medal”, with Christopher’s blessing became the “Reeve-Irvine Research Medal”. The medal recognizes an individual who has made highly meritorious scientific contributions in the area of spinal cord repair, and whose research has stood the test of time and scrutiny. The medal and a $50,000 cash award is provided through the generosity of the Joan Irvine Smith and Athalie R. Clarke Foundation, whose kindness has made it possible to continue to recognize the work of pioneering investigators whose research has brought us closer to cures for afflictions affecting the spinal cord.

Mark Tuszynski is a physician-scientist exploring the topics of spinal cord injury, degenerative disorders of the nervous system, and fundamental mechanisms underlying learning and memory. Dr. Tuszynski obtained his bachelor of science and M.D. degrees at the University of Minnesota, and completed residency training in neurology at Cornell University Medical Center / The New York Hospital. He then earned a Ph.D. in neuroscience at the University of California-San Diego. He has been a faculty member at the University of California-San Diego since 1991, and is currently the Director of the Center for Neural Repair and Founding Director of the UCSD Translational Neuroscience Institute.

Dr. Tuszynski has published over 190 research articles and 3 books. The overarching goal of his research is to develop effective therapies for untreatable neurological disorders. Dr. Tuszynski performed the first human clinical trial of gene delivery in the adult central nervous system: Nerve Growth Factor gene therapy for has received 15 awards for his research. His research is supported by the NIH, the Veterans Administration and has received 15 awards for his research.

2015 Annual Symposium

Nervous System Regeneration: Molecular & Cellular Mechanisms

BY Oswald Steward
On November 5th the RIRC hosted the Reeve-Irvine Research Medal symposium titled “Nervous System Regeneration: Molecular and Cellular Mechanisms” focused in axonal regeneration, neural repair and plasticity. We brought in experts who have made significant contributions in these areas. Many of our speakers have been involved in pre-clinical trials that have great potential for clinical applications in the very near future. The target audience for the symposium consisted of MD’s and RN’s in Neurological Surgery, Emergency Medicine, Physical Medicine and Rehabilitation and Orthopedic Surgery. Additionally the target audience included Ph.D.’s in Neurology, Anatomy & Neurobiology, Bioengineering and Translational Sciences.

The objective of the symposium:
• Identify terminology related to axonal growth and the limitations of experimental methods.
• Determine the benefits and issues with the study of central nervous system regeneration.
• Describe the biological phenomena of regeneration and how this research can be applied to regeneration-based therapies.

Course Director

Dr. Oswald Steward
Dr. Oswald Steward, Ph.D.
Director, Reeve-Irvine Research Center
Professor, Anatomy and Neurobiology,
University of California, Irvine

Distinguished Speakers

Mark Tuszynski, M.D., Ph.D Mark Tuszynski, M.D., Ph.D
Director, Center for Neural Repair
Professor, Department of Neurosciences
University of California, San Diego
Regeneration after spinal cord injury

Simone di Giovanni, Ph.D Simone di Giovanni, Ph.D
Chair, Restorative Neuroscience
Brain Sciences
Imperial College London
Axonal injury signaling and epigenietic cross talk for nerve regeneration

Daniel Geschwind, M.D., Ph.D Daniel Geschwind, M.D., Ph.D
Gordon and Virginia McDonald, Distinguished Professor
Department of Neurology, Psychiatry and Human Genetics, University of California, Los Angeles
Imperial College London
Integrative genomic investigation of neural repair

Murray Blackmore, Ph.D Murray Blackmore, Ph.D
Assistant Professor
Department of Biomedical Sciences
Marquette University
Transcriptional interventions to promote axon regeneration in the injured spinal cord

James Fawcett, Ph.D James Fawcett, Ph.D
Head of Department of Neuroscience
John van Geest Centre for Brain Repair
University of Cambridge
How can we enhance the regerative ability of CNS axons?

Armin Blesch, Ph.D Armin Blesch, Ph.D
Stark Neuroscience Research Institute
Department of Neurological Surgery
Indiana University, School of Medicine
Neural activity, regeneration and pain in spinal cord injury

Paul Lu, Ph.D Paul Lu, Ph.D
Associate Research Scientist
Center for Neural Repair
University of California, San Diego
Long-term human neural stem cell transplant after spinal cord injury: neurogenesis, gliogenesis and axon persistence

RIRC undergraduate research stars present at UCI’s Undergraduate Research Opportunity Symposium

BY Dr. Oswald Steward
RIRC undergraduate research stars present at UCI’s
Undergraduate Research Opportunity Symposium
Undergraduate researchers are an important part of our RIRC team, and two of them presented posters on their research in the Undergraduate Research Opportunity Symposium on May 14. Sara Jahangiri has been working with Erin Gutilla on a study of whether it is possible to activate the AKT/mTOR pathway by electrical stimulation of the cortex. The AKT/mTOR pathway is the one activated by deleting PTEN, and the idea here is that it might be possible to enhance regeneration of cortical axons by stimulation. Walter Guerrero has been working with Zach Gallaher on a study demonstrating that deleting PTEN and another gene called SOCS3 enhances regeneration of peripheral nerve axons. Walter is graduating in June and is applying for graduate programs. Congratulations to Sara and Walter and their excellent mentors Erin Gutilla and Zach Gallaher.

The 2016 Meet the Scientists Forum...

Highlighted by Special Guests Dr. Zoran Nenadic and An Do

BY Dr. Oswald Steward
2016 Meet the Scientists Forum with guest speakers Drs. Zoran Nenadic and An Do
For 16 years the Reeve-Irvine Research Center (RIRC) has been holding an annual “Meet the Scientists” forum, where community members and the public can come to hear about the progress RIRC members are making in spinal cord injury (SCI) research. The goal of this forum is to help educate and inform the community on new discoveries relevant to SCI. It is also an opportunity for people living with SCI and their family members to talk directly with our researchers and clinicians. This event is also important to our researchers as it has helped us target research toward the needs of the spinal cord injury population. What many may not realize is that the forum initially stemmed from a special request from Christopher Reeve to meet with SCI researchers to hear scientific updates. After his passing the event has continued on and is now opened up to the public and has been a valuable exchange of information.

This year, Drs. Zoran Nenadic and An Do demonstrated their Brain Computer interface study, a novel brain-computer-interface (BCI) technology created by the University of California, Irvine researchers that has allowed a man with paraplegia to walk for a short distance, with body weight support. This study received much attention from the media. We were excited to have them here in the iMOVE laboratory to personally talk to our guests at the event. Dr. David Reinkesmeyer also demonstrated his music glove study to help improve hand and arm function.

Other Reeve-Irvine Faculty members were also present to discuss areas of research including regeneration of connections in the injured spinal cord (Dr. Os Steward), pain following SCI (Drs. David Luo and Catherine Cahill) and exciting new ways to manipulate molecules that block regeneration (Dr. Melanie Cocco).

Drs. Reinkensmeyer and Sharp are recruiting volunteers for this study. Click this link to see the ad for more information on enrolling as a participant.

Look for information on next year’s Meet the Scientists here on our website and be sure to join our Facebook page. For additional information contact Tania Jope at (949) 824-5925 or

UCI Brain-Computer Interface Enables Paralyzed Man to Walk

Proof-of-concept study shows possibilities for mind-controlled technology.

BY iMove Lab
UCI Brain-Computer Interface Enables Paralyzed Man to Walk
A novel brain-computer interface technology created by University of California, Irvine researchers has allowed a paraplegic man to walk for a short distance.

In the preliminary proof-of-concept study, led by UCI biomedical engineer Zoran Nenadic and neurologist An Do, a person with complete paralysis in both legs due to spinal cord injury was able – for the first time – to take steps without relying on manually controlled robotic limbs.

The male participant, whose legs had been paralyzed for five years, walked along a 12-foot course using an electroencephalogram-based system that lets the brain bypass the spinal cord to send messages to the legs. It takes electrical signals from the subject’s brain, processes them through a computer algorithm, and fires them off to electrodes placed around the knees that trigger movement in the leg muscles.

Study results appear in the open-access Journal of NeuroEngineering & Rehabilitation. See the video at Even after years of paralysis, the brain can still generate robust brain waves that can be harnessed to enable basic walking, said Nenadic, an associate professor of biomedical engineering. We showed that you can restore intuitive, brain-controlled walking after a complete spinal cord injury. This noninvasive system for leg muscle stimulation is a promising method and is an advance of our current brain-controlled systems that use virtual reality or a robotic exoskeleton.

Months of mental training to reactivate the brain’s walking ability and physical therapy were needed for the study participant to reach the stage where he could take steps. Wearing an EEG cap to read his brain waves, he was first asked to think about moving his legs. The brain waves this created were processed through a computer algorithm Nenadic had formulated to isolate those related to leg movement. The subject later was trained to control an avatar in a virtual reality environment, which validated the specific brain wave signals produced by the algorithm.
“We showed that you can restore intuitive, brain-controlled walking after a complete spinal cord injury.” -Zoran Nenadic
This training process yielded a custom-made system, Nenadic said, so that when the participant sought to initiate leg movement, the computer algorithm could process the brain waves into signals that could stimulate his leg muscles.

To make this work, the subject required extensive physical therapy to recondition and strengthen his leg muscles. Then, with the EEG cap on, he practiced walking while suspended 5 centimeters above the floor, so he could freely move his legs without having to support himself. Finally, he translated these skills to the ground, wearing a body-weight support system and pausing to prevent falls. Since this proof-of-concept study involved a single patient, Do said, further research is needed to establish whether the results can be duplicated in a larger population of individuals with paraplegia.

Once we’ve confirmed the usability of this noninvasive system, we can look into invasive means, such as brain implants, said Do, an assistant clinical professor of neurology. We hope that an implant could achieve an even greater level of prosthesis control because brain waves are recorded with higher quality. In addition, such an implant could deliver sensation back to the brain, enabling the user to feel his legs.

Christine King, Po Wang, Colin McCrimmon and Cathy Chou of UCI contributed to the study, which received support from the National Science Foundation (grant 1160200).

Trials and Tribulations: Update on Stem Cell Trials for Spinal Cord Injury

BY Dr. Oswald Steward
Recent news for stem cell trials for spinal cord injury is decidedly mixed. On the one hand, the trials have proceeded without any reports of serious adverse effects, and there have been encouraging reports of improvements. On the other, it’s sad to report that the “Pathway” trial by the company Stem Cells Inc. has been terminated and the company announced it would wind down its operations. Also, another company sponsoring a stem cell trial for SCI (Neuralstem) announced a strategic reorganization to re-focus its priorities on small molecule therapies.

As background, most readers of “Spinal Connections” know there have been 3 ongoing trials of stem cell therapies for spinal cord injury. The first to be launched was the trial of oligodendrocyte precursor cells (OPCs) by the company Geron. The OPC trial was based on research by Hans Keirstead at the RIRC. Geron discontinued the trial but it was re-launched by the company Asterias. Next was the trial by the company “Stem Cells Inc,” which began in Switzerland, and was later extended to the United States and Canada. This trial involved transplantation of neural stem cells (NSCs) that differentiate into nerve cells, and glial cells. The foundation for the trial was research by Aileen Anderson and Brian Cummings at the RIRC. A third trial was launched by the company “Neuralstem” and is being run out of the University of California San Diego. This is an extension to spinal cord injury of an approach initially tested for amyotrophic lateral sclerosis (ALS). This trial involves a different type of proprietary neural stem cell. The OPC product of Asterias is derived by differentiating human embryonic stem cells (HESCs), whereas both of the NSC products were originally derived from cells harvested from aborted human fetuses.

The Asterias “SCiStar” trial-OPCs: In the Phase 1 clinical trial launched by Geron, five patients with neurologically complete, thoracic spinal cord injury received two million AST-OPC1 cells at the spinal cord injury site 7-14 days post-injury. Based on the lack of serious adverse events in this safety trial, Asterias launched the SCiStar trial, which will test three sequential escalating doses of “AST-OPC1” cells (20 million cells in the final cohort). Subjects are individuals who have suffered SCI at cervical level 5-7 and are neurologically complete (Asia A). Subjects will receive OPC transplants 14 to 30 days post-injury and will be followed by neurological exams and imaging procedures. A news release in October, 2015 announced a positive safety profile and absence of serious adverse events for the first 3 subjects who received the low dose, so the next cohort of 5 subjects will receive 10 million cells. According to the press release, the first patient who received OPCs at Shepherd Center in Atlanta exhibited neurological improvement from ASIA Impairment Scale (AIS) A to an AIS C at the 3 month assessment.

The Stem Cells Inc “Pathway Study”, NSCs: This was a trial involving the company’s proprietary human NSC line “HuCNS-SC®” for subjects with cervical SCI. Things seemed to be going well for this trial earlier in the spring of 2016. At the 2016 American Spinal Injury Association (ASIA) annual meeting in Philadelphia in April, Dr. Stephen Huhn, Chief Medical Officer and VP of Clinical Research at Stem Cells Inc. gave an update. The 6-month results from Cohort I (6 subjects) revealed improved muscle strength in 5/6 subjects, improved dexterity and fine motor skill in 4/6 patients and no serious side effects. On this basis, Cohort II had been launched, which was to be a randomized, single-blinded study of 40 AIS-B subjects. By late May, 11 subjects had received transplants in Cohort II.

But then suddenly on May 31 Stem Cells Inc. announced that it would terminate the study and close out operations. The 6,9, and 12-month results from Cohort I revealed encouraging patterns of improvements, but the effect was smaller at the 12 month time point. Because of this, the Company conducted an interim analysis of data from Cohort II. There were differences in motor strength that favored the treatment group, but the effect size was small and the company concluded that the study would be unlikely to achieve the primary endpoint objective.

For perspective regarding the issue of “effect size”, it’s important to emphasize the difference between preclinical studies in animals and human clinical trials. In most studies with animals, scientists make every effort to be sure that injuries are comparable and everything except the treatment is similar between groups. This practice of “minimizing variability” is so that it is possible to detect treatment effects. The problem is that human SCIs are highly variable, so if “effect size” is small, it’s harder to achieve a statistically significant result in a clinical trial.

Of course there is major disappointment that the “Pathway” trial is terminated. There will be a lot to learn from the Stem Cells Inc. experience, both in terms of the science and the economics of developing therapies for SCI. This is another practical lesson that limited financial resources make it difficult for small companies to continue when it becomes clear that the path to a therapy is longer than expected.

Neuralstem NSI-566/cSCI: The trial by Neuralstem is a phase I trial in which 5 subjects received six injections in, or around, the injury site, using the same cells and similar procedure as the company’s ALS trials. Subjects also receive physical therapy and immunosuppressive therapy. The 5th subject received the cells in July 2015. At the time of this writing, there are no updates on the results of the Neuralstem trial except that there have been no reports of adverse events.

However, on May 20, 2016 Neuralstem announced a “Plan of reorganization to further align business with strategic intent”. According to the press release: “The company's refocused strategy emphasizes its commitment to prioritize the small molecule platform, undertake business development efforts to secure alternative funding and partnerships for its stem cell assets.... Accordingly, the corporate reorganization includes a workforce reduction across all divisions that will result in significantly lower operating expenses while retaining the expertise needed to implement the company's refocused strategy”. It remains to be seen how this reorganization will affect any further trials of Neuralstem’s product for spinal cord injury.

CST Regeneration in the Chronic Injury Setting

BY Steward Lab
CST Regeneration
Most of our readers know that the "Corticospinal Tract Regeneration Project" has been the focus of the Steward Research Group for years, and for the last 5 years has involved a multi-investigator collaboration that has been following up on a paper the team published in 2010. The original paper, published in Nature Neuroscience, showed that it was possible to induce regeneration of the corticospinal tract (CST) following spinal cord injury by deleting a gene called phosphatase and tensin homolog (PTEN). The latest papers from the Steward lab, published in 2014 and earlier this year, showed that CST regeneration was accompanied by recovery of motor function. (See next article: PTEN Deletion Post SCI Regeneration and Recovery by Sam Maddox)

In a new breakthrough, our collaborator Dr. Kai Liu, who was first author on the Nature Neuroscience paper and now has his own lab at Hong Kong University, published a very important paper showing that is possible to induce CST regeneration in the chronic setting either 4 months or 1 year after a spinal cord injury!
the Journal of Neuroscience The paper appeared in the July issue of the flagship journal of our field, the Journal of Neuroscience, and was featured on the cover. In the study, Dr. Liu used the same genetic deletion strategy that was used the original paper. Mice received spinal cord injuries and then 1 year later, received an injection of a viral -based vector into their cortex, which produces a protein that deletes PTEN from the nerve cells that give rise to the CST. After deleting PTEN, CST axons regenerated past the injury and formed new connections. The discovery that regenerative ability can be rebooted even one year after an injury greatly extends the window of opportunity for regenerating connections in the injured spinal cord. Next steps will be to determine if the regeneration is accompanied by reversal of paralysis.

PTEN Deletion Post SCI Regeneration and Recovery

BY Sam Maddox
Over the last few years we have written several times about a nifty genetic manipulation that reboots key nerves in the spinal cord to regenerate in a big way. Starting back in 2008, Zhigang He, at Harvard, got damaged optic nerves going again by deleting PTEN, a tumor suppressor gene that cancer researchers had come across back in the 1990s; this enzyme acts as a sort of brake when axons attempt to regenerate after injury.

In the world of cancer, of course, the idea is to keep the growth brake on; in spinal cord repair, it's just the opposite. Anyway, in later experiments, when PTEN was removed, the corticospinal tract (CST) regenerated in lab animals - important because the CST comprises crucial wiring for arm and hand function.

The most recent research, from Camilla Danilov and Oswald Steward at the Reeve-Irvine Research Center at the University of California, Irvine, takes a big step toward clinical relevance. In all previous experiments, animals used in the tests had PTEN deleted before they were spinal cord injured. This time, they took the PTEN brakes off after animals had been paralyzed.

The paper, out in the journal Experimental Neurology, is titled "Conditional genetic deletion of PTEN after a spinal cord injury enhances regenerative growth of CST axons and motor function recovery in mice."
Improved recovery of hand function in rats due to PTEN deletion: red=animals with PTEN deletion; blue and green=two untreated control groups
From the abstract: Previous studies indicate that conditional genetic deletion of phosphatase and tensin homolog (PTEN) in neonatal mice enhances the ability ofaxons to regenerate following spinal cord injury (SCI) in adults. Here, we assessed whether deleting PTEN in adult neurons post-SCI is also effective, and whether enhanced regenerative growth is accompanied by enhanced recovery of voluntary motor function. These results indicate that PTEN deletion in adult mice shortly post-SCI can enhance regenerative growth of CST axons and forelimb motor function recovery.

The new study used a gene delivery vector to delete PTEN 20 minutes after a moderate contusion injury at C5. The animals without PTEN could grip and grasp much better than control (injured but untreated) animals.

Why this injury model? From the paper: ... the injury model used in this study was a moderate cervical contusion at C5 centered on the midline of the spinal cord that produced bilateral tissue damage and bilateral function deficits. We chose this injury model for its human relevance. More than 50 percent of spinal cord injuries are at the cervical level, impairing both lower and upper extremities and the most common type of injury in humans is the contusive type. Another thing the scientists wanted to know is if this technique would give the CST axons a boost. The answer is yes, although for reasons that are not clear, CST growth is less than in previous experiments. From the paper: The regenerative growth seen here resembles what has been previously reported following spinal cord injury ... The extent of the regenerative growth appears less extensive, however, although direct comparisons are difficult because the site and nature of the injury are different (C5 contusion vs. T8 dorsal hemisection or crush). Further studies will be required to address this issue.

In conclusion, the present study demonstrates enhanced recovery of forepaw gripping and grasping function and enhanced regenerative growth of injured CST axons with conditional genetic deletion of PTEN in adult mice shortly after a spinal cord injury. These results suggest that manipulations of PTEN or the downstream mTOR pathway may be a viable target for therapeutic interventions to promote axon regeneration after spinal cord injury.

Induced Pluripotent Stem Cells: A recent discovery that could lead to personalized medicine for SCI

BY Steward Lab
IPS cells have the potential to make any cell in the adult body, including the cells that make up the spinal cord and brain.
My name is Joe Bonner and I am a postdoctoral fellow in the lab of Dr. Steward at the Reeve-Irvine Research Center and I study the use of human neural stem cells for the treatment of spinal cord injury and my work is currently funded by the California Institute for Regenerative Medicine (CIRM) through a training grant administered at the Bill and Sue Gross Stem Cell Center here at UCI. Stem cells are a special type of cell that have the potential to repair tissue by replacing cells that were lost due to spinal cord injury. Stem cells are present in the brain and spinal cord and they contribute to the normal function of the nervous system throughout life. In the event of a spinal cord injury, resident stem cells respond and make an attempt to repair the damage but there are simply not enough stem cells to fix such serious injuries. In my research, I transplant neural stem cells in an effort to improve tissue repair and to restore the neural connections between the brain and the body. In addition to transplants of stem cells I also administer "growth factors" to improve the function of the transplanted stem cells and at the same time I also manipulate the function of the PTEN/mTOR pathway, which Dr. Steward has previously shown can give the injured nerve cells in the spinal cord a regenerative boost. The goal of my work is to understand how stem cells can contribute to the repair of spinal cord injury and to ultimately create a treatment for people who have suffered a spinal cord injury.

The human neural stem cells that I use in my research are made from a relatively new kind of stem cell called induced pluripotent stem cells, or IPS cells. IPS cells were first described in 2006 by Shinya Yamanaka, who won the Nobel Prize for the discovery in 2012. In the short time IPS cells have been around scientists have begun to understand how they could be applied to treat illness and injury. IPS cells have many characteristics that make them an interesting resource in our search for a treatment for spinal cord injury.
Induced Pluripotent Stem Cells: A Recent Discovery that Could Lead to Personalized Medicine for SCI
IPS cells are made by "reprogramming" or "inducing" an adult cell to become a stem cell. This means that stem cell scientists are able to take a common cell found in an adult, such as a skin cell, and to change that skin cell into a stem cell. This procedure eliminates many of the difficulties that are associated with embryonic stem cells while producing a stem cell with many of the same characteristics. The most intriguing benefit of IPS cells is that they could be made for each individual patient. If an IPS cell therapy was designed to use a patient's own cells then there would be no need for the patient to take additional medications to prevent an immune reaction or transplant rejection.

IPS cells have the potential to make any cell in the adult body, including the cells that make up the spinal cord and brain. IPS cells can be grown for a very long time in a culture dish. This means that cells can be expanded from a small number into enough cells to conduct experiments and to eventually treat human patients. Before IPS cells were discovered, the only type of cell that had these characteristics were embryonic stem cells. Although embryonic stem cells (ESCs) may prove useful for treatment of spinal cord injury, ECS's are not "personalized" so patients who receive ESC transplants have to take immunosuppressant drugs to prevent rejection.

I have been ableto demonstrate that human neural stem cells derived from IPS cells can survive in the injured spinal cord and make nerve cells (neurons) and support cells (glia) after transplantation. My continuing research seeks to determine if these transplanted stem cells can communicate with injured nerve cells in the injured spinal cord and if those lines of communication can improve the recovery of function in an animal model of spinal cord injury.

Chronic Pain Causes Brain Inflammation. Why Should You Care?

BY Cahill Lab
Chronic Pain Causes Brain Inflammation
Research Findings: Pain is a multidimensional experience, and how much the pain is 'bothersome' significantly impacts the quality of life of the sufferer. In fact, the emotional component of pain has been argued to be a great metric in measurements of quality of life. There is extensive interaction between systems involved in pain processing and brain regions responsible for mood. Notably, chronic pain co-exists with depression, which is thought to involve imbalance in a brain system that uses the neurochemical dopamine. Dr. Cahill recently published a paper in Journal of Neuroscience (available as a free open access article on their website at The Journal of Neuroscience ) that neuro-inflammation, as the result of ongoing pain caused by nerve damage (neuropathic pain), occurs in brain regions important for reward and mood. Reward circuitry is important for how we feel (mood), our motivation, and our ability to feel pleasure. Her research team identified that non-neuronal brain cells, called microglia, alter brain activity important for producing reward. This research identifies a pathway from microglia to neurons that causes suppression of the neurochemical dopamine and thus likely contributes to many of the devastating sequelae of chronic pain, including the poor response many pain patients have to their opioid prescription medications, debilitating affective disorders, and substance abuse (Figure 1). Her research is supported by the recent clinical trial that reported minocycline, a microglial inhibitor, did not alter pain intensity, but diminished how bothersome pain is in patients with neuropathic pain. This publication was recently picked up by multiple media sites including the OC Register (Wednesday, June 17th) as well as various websites including: MD magazine, Free Press Joumal, Medical News Today, Neurology Advisor and Psychiatry Advisor.

Why is this research important? Approximately, 20-25% of Americans suffer from chronic pain making it the most common form of chronic illness under the age of 60. The Institute of Medicine estimates that it costs our society $635 billion spent per year. Treating non-cancer chronic pain is a challenge for physicians because many patients do not respond to typical analgesics, such as ibuprofen-like drugs or opioids such as morphine. Additionally, treating patients with opioids long term has been come controversial because of the high incidence of addiction to pain medications, and there are studies questioning the effectiveness of opioids for treating certain types of chronic pain, especially those of nerve injury origin. Dr. Cahill's study imposes a paradigm shift in the field of chronic pain because it identifies that chronic pain can cause neuro-inflammation in brain regions important for reward experiences. The work identifies novel signaling and biophysical mechanisms by which microglia alter neuron activity in reward circuits, important for mood, motivation, and pleasure. The impact of our research is not restricted to the problem of pain, but is broadly relevant to mood disorders such as depression and substance abuse. Both of these medical conditions are associated with disruption of reward circuitry. Chronic pain patients are more than twice as likely to suffer anxiety and depression, and co-existence of pain with mood disorders is reported to be 30-100% depending on the causes of chronic pain. Importantly, chronic pain is second only to bipolar disorder as the major cause of suicide among all medical illnesses. Dr. Cahill's study suggests that treatments that target neuroinflammation will be an important novel therapy to alleviate many of the troubling emotional sequelae of chronic pain. Our study also has implications for why some chronic pain patients become addicted to their opioid analgesics used for managing chronic pain.

Next steps: There are many directions for this research. First, we would like to establish that the circuitry changes account for affective-like behaviors. We have a novel compound from Dr. Yves De Koninck that has the potential to restore function and normalize reward-like behavior. Once these compounds get approval for clinical trials, we will test whether restoring reward function is therapeutic in a chronic pain population. We would also like to follow this up with clinical research pursuing imaging studies to identify whether chronic pain patients also show the same disruption in reward circuitry.

Take home message: Chronic pain is a devastating disease that negatively affects a person's quality of life. Not only do patients have to live with pain everyday; they also commonly suffer from depression. Our studies show that chronic pain changes your brain in areas important for mood. Importantly, we provide proof that the prevalence of depression in chronic pain patients is likely an organic disease and is not psychological. The work indicates that changes in the brain caused by pain likely cause this mood disorder; depression is not simply a consequence of their state of mind from having to live with pain. We have identified multiple proteins thet can be targeted for translational medicine to determine their effectiveness in improving quality of life for those suffering from chronic pain, as well as potentially for Major Depressive Disorders. Our research identifies a pathway that likely contributes to many of the devastating sequelae of chronic pain, which include the poor therapeutic response of oploid analgesics in a subset of chronic pain patients, debilitating affective disorders and substance abuse.

The Legacy of Frank Freed

The Legacy of Frank Freed
It is difficult to say goodbye to our dear friend and supporter of our Center. On April 22, 2015 Frank Holston Freed who was born on September 17, 1924 passed away due to congestive heart failure. He is survived by his wife Evelyn Freed who has generously supported the RIRC since its inception. Frank enlisted in the Army in 1942 and was a soldier in World War II losing his arm in France. Frank graduated from Wheaton College in 1948 with a BA Degree in Philosophy and from Fuller Theological Seminary with a BD Degree in Theology. He was the pastor of Bethany Baptist Church in West Covina, California from 1951-1957. He received an MA Degree in History from Stanford University in 1958, and was a founding Pastor of Valley Church in Cupertino, California from 1959-1969. Frank received a Secondary Teaching Credential in History at USC in California in 1970, and then went to Fuller Theological Seminary School of Psychology where he earned a Ph.D. Degree in Psychology in 1974. Frank was a Clinical Psychologist in private practice in Orange County, ending his career as Director of Counseling at the Crystal Cathedral for ten years until his retirement. In 1997 Harold Shaw Publishers published Frank's book "Breaking Free When You're Feeling Trapped". He also published another book titled "Breaking Free" about bettering your life through attitude. He was credited with making a positive impact on many people's lives with his loving spirit and educational counsel. The generosity and support that Evelyn and Frank have given to our Center over the years has made a lasting impact on spinal cord injury research efforts. Frank has left a very large footprint and will be sorely missed by us all at the Reeve-Irvine Research Center.
FRANK FREED MEMORY FELLOWSHIP: Please consider helping us with a donation to establish the Frank Freed Memory Fellowship. The name is a double entendre; the fellowship is to honor Frank Freed via a fellowship for research on memory.
Give Now

Using Stem Cells to Improve Bladder Function After a Low Spinal Cord Injury

BY Havton Laboratory
Using Stem Cells to Improve Bladder Function after a Low Spinal Cord Injury
Stem cells have the potential to become any cell of the body and after a spinal cord injury, researchers have used them to replace everything from the supporting cells of the nervous system to the actual cells that transmit information from the brain to different parts of the body. The Havton lab at the Reeve-Irvine Research Center and the Sue & Bill Gross Stem Cell research Center at UC Irvine is utilizing stem cells to replace cells located in the low lumbar and sacral regions of the spinal cord that are injured after a trauma to the lumbosacral spinal cord and nerve roots. Physicians often refer to these injuries as conus medullaris or cauda equina injuries. After a low spinal cord injury the bladder may become underactive because spinal cord motor neurons that normally signal the bladder to contract are either dead or dying. As a result, the bladder tends to fill up more than it should, because the affected individual is unable to sense the fullness of the bladder or empty the bladder voluntarily. Such over-filling of the bladder can lead to urinary tract infections, kidney disease or overflow incontinence. Ongoing research in the Havton lab focuses on the nerve cells in the spinal cord that normally contract the bladder and cause voiding. For this purpose, stem cells are used in laboratory models to replace the injured and lost motor neurons. The goal of the study is for cell replacement therapy to improve bladder function and the quality of life of people living with a low spinal cord injury.
In collaboration with Drs. Harley Kornblum and Bennett Novitch at UCLA, the Havton lab has developed a method to convert stem cells into a mix of motor neurons and support cells in the dish and transplant the cells into the spinal cord of rats. Ongoing studies are using a cauda equina injury model and the cell transplantation strategies to determine feasibility of this approach to reverse functional deficits of the bladder. Special attention is paid to see whether the transplanted cells may survive over long periods of time after transplantation and reconnect with the peripheral targets in the pelvis to restore bladder function. The collaborative and translational studies have received support from California Institute of Regenerative Medicine (CIRM). Dr. Arthi Amin, a post-doctoral fellow in the Havton lab, will present results from this ongoing study in November at the annual meeting for the Society for Neuroscience in Washington, D.C.

Chronic Pain Changes Your Brain in Areas Important for Reward and Emotion

BY Cahill Lab
Chronic Pain Changes Your Brain In Areas Important For Reward And Emotion
The most effective class of drugs available for treating moderate to severe pain is opioid drugs, such as morphine, hydrocodone (Vicodin®) and oxycodone. Opioids have been used (and abused) for centuries with uses ranging from religious rituals to treatment of dysentery, however, their prominent use in treating moderate to severe pain in modern medicine will undoubtedly continue for the foreseeable future, due to the lack of alternative choices. Most experts would agree that despite the fears of addiction and the plethora of side effects that may limit use, opioid drugs are superior analgesics for the treatment of post-operative pain, traumatic injury-related pain, and cancer pain. However, their long-term use in management in chronic non-malignant pain is now being challenged, where concerns about safety and efficacy are debated.
Over the past 2 decades there has been a tremendous effort by basic scientists, biotechnology companies and the pharmaceutical industry to develop new drugs to alleviate pain. Various drug candidates made it from preclinical testing to clinical trials, only to have failed and consequently many companies have now abandoned their pain programs. Those new drugs that have made it to market are primarily restricted to spinal delivery, limited to use in terminal cancer patients, or are based on success of drugs with similar chemical structure (e.g. pregabalin, which was developed after the success of off-label use of gabapentin which rose to over 1 billion annual sales in the USA). Some analysts blame the lack of drug development for pain drugs in the trial design and/or the patient cohort (type of pain patient recruited for the trial). However, there is also a debate about whether the preclinical testing can capture pain.
Pain is a multidimensional experience comprised of sensory, cognitive, and affective (emotional) components, which are processed within discrete but interacting brain structures. It is well accepted that many chronic pain states, including those that result from spinal cord injury, are accompanied by dramatic sensory disturbances that result in pain hypersensitivity (allodynia – painful experience to something normally not painful and hyperalgesia – exaggerated response to something normally painful) and tonic (unprovoked) ongoing pain. Preclinical animal pain model testing captures the sensory component by measuring the time to respond to a painful stimulus. However, the emotional affective component, or how much the pain is ‘bothersome’ or unpleasant significantly impacts the quality of life of the sufferer. Most animal models of chronic pain typically rely on sensory/threshold measures of pain, but the emotional component of pain has been argued to be a greater measure of quality of life than its sensory component, and there is now a concerted effort to develop assays to capture this aspect of pain with the goal of better predictability of drug candidates. Capturing this aspect of pain is a challenge because you can’t ask a mouse or rat how it feels.
Future directions - How do we proceed? There is fascinating new research indicating that the “bothersome” unpleasant component of chronic pain engages parts of the brain called the limbic system. Within the limbic system are brain regions important for being able to experience something we like (rewarding) or something we try to avoid (aversion). The key point is that pain and reward are opposite processes, but are processed within overlapping or interacting brain structures - see Figure 1. This is important because stimuli that are rewarding such as food and pleasurable music DECREASE pain, and conversely pain can impair reward processing (pleasure). So chronic pain can cause an “anhedonic state” in which a person can’t experience pleasure from activities usually found enjoyable (e.g., exercise, hobbies, music, sexual activities or social interactions). In fact, chronic pain is second only to bipolar disorder as the major cause of suicide among all medical illnesses, further highlighting how devastating this condition is. The interplay between reward pathways and pain validate the importance of these brain areas, not only in why acute pain becomes chronic, but also the minimal effectiveness of opioid analgesics in treating many types of chronic pain (including that of neuropathic origin).

On-going Studies: Dr. Cahill and her research team recently identified that there is dysfunction of reward circuitry in an animal model of neuropathic pain. So, pain changes reward circuits. Reward (pleasure) decreases pain perception, so disrupting reward circuits may increase pain because it makes it more unpleasant. This is a major discovery, and the Cahill lab is now following up with research aimed at understanding the mechanisms responsible for the dysfunction of brain circuitry involved in emotion and reward in models of chronic pain. They are also preparing a proposal to seek pilot data for a clinical study aimed at novel therapies that will alleviate the emotional, affective component of pain. This is early stage research—the follow up to a fundamental discovery, so additional data are needed before a clinical study can be launched. The Cahill lab is seeking federal funding, but this is where private contributions could make a HUGE difference, allowing these scientists to collect the critical preliminary data that would allow a clinical study of novel therapies to address chronic pain.

News Reports of Recovery After Transplants of Olfactory Cells with Peripheral Nerve Bridges

BY Dr. Oswald Steward
Dr. Oswald Steward
Many of you will have seen news stories reporting functional regeneration of connections that enable movement in a man that received transplants of olfactory cells. This approach is a clinical realization of decades of research by a scientist who received our Reeve-Irvine Research Medal in 2005 (Geoff Raisman). The findings are provocative, and the overall study reflects a huge effort by a skilled team of researchers and medical doctors. Unfortunately, though, the situation is not as simple as implied in most of the news stories. So, what is this all about, and what does it mean for those of you living with paralysis?

First the science: the overall approach builds upon years of research on regeneration of nerve connections from the nose to the brain. The ability to smell is mediated by nerve cells in the nose called olfactory receptors, which are embedded in a structure called the nasal mucosa, which is made up of receptor cells and mucosal cells. The olfactory receptors respond to chemicals in the air, and communicate via connections (axons) that project into the brain. The olfactory receptors in the nose turn over throughout life (that is, the cells die and others are born), which is different than almost any other part of the nervous system. When new cells are born, they have to grow their axons from the nasal mucosa in the nose into the olfactory bulbs, which are inside the skull. The olfactory bulb is connected to the brain by the olfactory nerve. To grow from the olfactory mucosa to the brain, the axons grow through the bony structure between the nose and the brain called the cribriform plate, and there is lots of evidence that growth is enabled by a special population of glial cells there called olfactory ensheathing cells (OECs). Dr. Raisman and other scientists have provided strong experimental evidence that OECs have special properties in terms of supporting axon growth, and many scientists have tried different ways of transplanting either OECs or the entire nasal mucosa into the injured spinal cord to promote regeneration.

Based on the studies in animals, quite a few people throughout the world have received a highly experimental therapy involving transplants of olfactory mucosa into the spinal cord. This experimental therapy is not available in the United States, but has been offered in Portugal and elsewhere, and some Americans have traveled to other countries to receive the transplants. These weren’t clinical trials, however; they were experimental therapies without controls or followup testing, so there’s no scientific data on outcomes. Also, there are concerns about the approach of transplanting olfactory mucosa because of the recent finding of a tumor that developed in the spinal cord in a patient that received such a transplant (see our Spring 2014 newsletter).

It’s important to emphasize that this new study involves cells that were isolated from the olfactory mucosa, not the olfactory mucosa itself, so the risk of tumor formation is hopefully less. Another good thing about this new study is that it was actually a clinical trial with an experimental and control group with extensive pre- and post-operative testing, so there is a lot of data. The patients were a total of 6 men between the ages of 22 and 26; 3 patients received the treatment, 3 did not, and all were tested extensively. The study reported outcomes 1 year after cell transplantation. The treatment in this new study, which was carried out in Warsaw Poland, was to transplant OECs that were harvested from the patient (autologous transplants) along with small pieces of peripheral nerves that were inserted to provide a bridge across the injury site. The first step was a complicated surgery to remove the olfactory mucosa.

The olfactory mucosa was then dissociated (meaning broken up so that individual cells are in a mixture—imagine rice mixed with water) and the cells were transferred to a tissue culture dish for several days. The cells were characterized extensively while growing in culture, and at the end of the cell culture period contained OECs as well as other cell types. Then, each patient received another surgical procedure to open the spine and visualize the spinal cord so that the transplant could be done. Then, there was a lot of rehabilitation and testing.

Of the 3 people who received transplants, 2 exhibited improved function on the ASIA scale, the third did not improve on the ASIA scale, but did experience some improvement in sensation just below the injury. The main recovery in all patients was between 6 and 12 months post-transplant. For the man who was featured in the news reports who exhibited the greatest recovery, the first signs of recovery were 6 months following the treatment, and involved tingling sensations below the injury. By 8 months, the patient recovered some ability to feel touch below the injury. By 1 year, the patient had …a slight voluntary flexion of the right hip which qualified for conversion of the ASIA grade from A to C.

It’s important to emphasize how the authors summarized the results: … patients who underwent the operation of OEC transplantation combined with intense pre- and postoperative neurorehabilitation showed modest neurological signs of recovery. This highlights the fact that was a carefully done and carefully interpreted study with a lot of details, although even with that, some of the claims are provocative. The title of the article claims “functional regeneration” (meaning growth of axons across the injury site). This claim was based largely on neurophysiological studies involving stimulation and recording of muscle responses (motor evoked potentials). This would be extraordinary if true. The authors were actually a lot more conservative in the paper itself, noting that even when injuries are functionally complete, there are usually some spared connections that could recover the ability to transmit. In fact, the authors conclude that the neurological recovery in transplanted patients may have been …a combination of remyelination of spared demyelinated axons, stimulation of regeneration of lesioned axons towards the target host neurons, and reactivation or sprouting of surviving axons.

It’s also important to note that the man who was featured in the news reports became paralyzed as a result of a stab injury, which caused extensive but incomplete laceration of the spinal cord leading to paralysis of the legs. This is a different situation than occurs with most spinal cord injuries that result from blunt force trauma like car accidents, diving injuries and falls, which cause contusion injuries. It is possible that the greater recovery in this patient is due to the type of injury.

So, the important thing is that this study was carefully done and produced a lot of scientific data that will form the basis for future studies. The surgical and cell culture procedures used here are complicated, and even in the best case, the neurological recovery was modest. The cost of the therapy would likely be several hundred thousand dollars per patient because of two surgical procedures, the lab work to grow the cells, and intense rehabilitation that extended for months. Only time will tell whether this could ever be adopted as a practical and effective therapy.
This was published in an open access journal, so you can download the original article (
Reference: Tabakow, P., G. Raisman, W. Fortuna, M. Czyz, J. Huber, D. Li, P. Szewczyk, S. Okurowski, R. Miedzybrodzki, B. Czapiga, B. Salomon, A. Halon, Y. Li, J. Lipiec, A. Kulczyk and W. Jarmundowicz (2014). "Functional regeneration of supraspinal connections in a patient with transected spinal cord following transplantation of bulbar olfactory ensheathing cells with peripheral nerve bridging." Cell Transplant

Neural Stem Cell Clinical Trial

Chronic Pain Changes Your Brain In Areas Important For Reward And Emotion
In early October, the company Neuralstem Inc. announced that the first patient had been treated in their new Phase I clinical trial involving “Neural Stem Cells” (NSCs). In this trial, four patients with chronic thoracic level injuries (1-2 years post injury) will receive NSC transplants into the injury site. This trial is under the direction of Dr. Joseph Ciacci, MD, UC San Diego School of Medicine and neurosurgeon at UC San Diego Health System. Much of the pre-clinical work with the NSI-566 cells in spinal cord injury was conducted at UC San Diego School of Medicine by Martin Marsala, MD, professor in the Department of Anesthesiology.
As described in our previous newsletters (see Spinal Connections #22, winter 2012), NSCs are stem cells that are already specified to a neural lineage. They are able to multiply and differentiate into all of the cell types of the nervous system including neurons, astrocytes, and oligodendrocytes. The goal of the treatment being tested in this trial is to inject NSCs into the injury site, where it is hoped that they will develop into a tissue bridge that will allow axons to grow across the injury.
The goal here is a bit different from other ongoing trials of stem cells for spinal cord injury. For example, in the Asterias trial, which continues the one started by Geron, the rationale was to use oligodendrocyte precursor cells (OPCs) derived from embryonic stem cells, which are injected near the site of injury in the hope that they will restore myelin and/or provide growth factors to help repair. In the ongoing trial by Stem Cells Inc., their proprietary NSCs are injected near the injury in the hope that they will develop into nerve cells and glial cells and/or provide growth factors to promote repair.
Neuralstem’s proprietary NSC line is the one that was used for the ongoing ALS trial, in which 30 patients received transplants. This was primarily a safety trial, and no adverse events have been reported so far. A follow-up trial with larger numbers of patients to test efficacy for ALS is being planned.
One cautionary note: Dr. Steward has also been studying NSCs as a means of bridging lesion sites. One surprising discovery this year involves NSCs that were treated with high concentrations of growth factors to promote their survival and expansion. In an experiment in rats, Dr. Steward discovered that about half the rats developed ectopic colonies of cells at long distances from the transplant. For example, following transplants into lesion sites at the thoracic level, colonies of stem cells were found in the cervical spinal cord and the brain. This work was first published in the journal “Cell” in early 2014 and a follow-up article was published in the Journal of Neuroscience in early fall. Dr. Steward is carrying out further studies to determine whether these colonies are harmful or not.